Dame Kate Bingham is a Managing Partner at SV Health Investors. See sector focus and contact routes.
Dame Kate Bingham is a Managing Partner at SV Health Investors, where she co-leads the firm’s biotech franchise and has managed venture capital funds for over 30 years since joining in 1991. Her investment thesis focuses on building high-value biotech companies that develop transformational medicines across small-molecule, biotherapeutic, and gene therapy sectors in the UK, EU, and US. While specific check sizes and lead/follow behavior are not explicitly detailed in available sources, she has personally led many investments that resulted in the launch of 30 novel drugs, including six first-in-class therapeutics. Notable portfolio companies include Autifony, Bicycle Therapeutics, Kalvista Pharmaceuticals, and Pulmocide, reflecting her focus on drug discovery platforms and clinical-area-specific development. Bingham is also distinguished by her public service as Chair of the UK Vaccine Taskforce in 2020, where she led the UK’s rapid procurement and manufacturing of COVID-19 vaccines, earning a DBE for her contributions. She holds a first-class Biochemistry degree from Oxford and an MBA from Harvard Business School as a Baker Scholar, grounding her ventu
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in London.
Investors like Kate Bingham · Full investor directory · Investor access · Company funding database